Press Release
Investor Relations
14 May 2007
The Company is restating its Consolidated Financial Statements for the year to December 31, 2005 to restate the value ascribed to in-process research and development and goodwill acquired as a result of the Transkaryotic Therapies, Inc acquisition on July 27, 2005. For further information see the Form 8-K filed with SEC on February 20, 2007.
The company intends to restate its consolidated financial statements for the year ended December 31, 2005 in its Annual Report on Form 10-K for the year ended December 31, 2006 which it anticipates filing in the week commencing February 26, 2007. Investors should look to the restated financial statements included within the Form 10-K for the year ended December 31, 2006 when they become available.
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
